First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Planchard, Byoung Chul Cho, Jhanelle Elaine Gray, Luis G. Paz-Ares, Mustafa Ozguroglu, Augusto E. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike De Wit, Yu Gu, Catherine Wadsworth, Phillip A. Dennis, Scott Joseph Antonia
Institutions: Institut Gustave Roussy, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Moffitt Cancer Center, Hospital Universitario 12 De Octubre, Istanbul University-Cerrahpaşa, Istanbul University, Tennessee Oncology, Hospital Universitario Virgen Macarena, Kanagawa Cancer Center, The University of Sydney, Westmead Hospital, Kansai Medical University Hospital, Chungbuk National University, Chungbuk National University Hospital, Vivantes Klinikum, AstraZeneca (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2946880337